These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29743023)

  • 21. Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II).
    Ishibashi Y; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Garcia-Garcia HM; Bartorelli AL; Whitbourn R; Chevalier B; Abizaid A; Ormiston JA; Rapoza RJ; Veldhof S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1715-26. PubMed ID: 26585622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Very Late Restenosis Following Bioresorbable Scaffold Implantation.
    Okuno T; Yahagi K; Horiuchi Y; Aoki J; Simonton CA; Rapoza R; Saito S; Kimura T; Tanabe K
    JACC Cardiovasc Interv; 2017 Sep; 10(18):e167-e169. PubMed ID: 28866033
    [No Abstract]   [Full Text] [Related]  

  • 26. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R.
    Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C
    EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population.
    Wiebe J; Gilbert F; Dörr O; Liebetrau C; Wilkens E; Bauer T; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):975-81. PubMed ID: 26269391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry.
    Cortese B; di Palma G; Cerrato E; Latini RA; Elwany M; Orrego PS; Seregni RG
    J Interv Cardiol; 2017 Oct; 30(5):427-432. PubMed ID: 28853189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study.
    Tang XF; Ma YL; Song Y; Xu JJ; Yao Y; He C; Wang HH; Jiang P; Jiang L; Liu R; Gao Z; Zhao XY; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Cardiovasc Diabetol; 2018 Aug; 17(1):114. PubMed ID: 30107794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
    Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of potential substrates for restenosis and thrombosis in overlapped versus edge-to-edge juxtaposed bioabsorbable scaffolds: Insights from a computed fluid dynamic study.
    Rigatelli G; Zuin M; Dell'Avvocata F; Cardaioli P; Vassiliev D; Ferenc M; Nghia NT; Nguyen T; Foin N
    Cardiovasc Revasc Med; 2018 Apr; 19(3 Pt A):273-278. PubMed ID: 28918876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.